The effectiveness of colistin/levofloxacin compared to colistin/meropenem in the treatment of ventilator-associated pneumonia (VAP) caused by carbapenem-resistant Acinetobacter baumannii: a randomized controlled clinical trial
暂无分享,去创建一个
[1] Zhenjiang Bai,et al. Comparison of diagnostic criteria for acute kidney injury in critically ill children: a multicenter cohort study , 2022, Critical Care.
[2] M. Assefa. Multi-drug resistant gram-negative bacterial pneumonia: etiology, risk factors, and drug resistance patterns , 2022, Pneumonia.
[3] F. Shafiee,et al. In vitro synergistic effect of colistin and ampicillin/sulbactam with several antibiotics against clinical strains of multi-drug resistant Acinetobacter baumannii. , 2021, Indian journal of medical microbiology.
[4] L. De Martino,et al. Acinetobacter baumannii: Its Clinical Significance in Human and Veterinary Medicine , 2021, Pathogens.
[5] G. Guyatt,et al. Diagnosis of ventilator-associated pneumonia in critically ill adult patients—a systematic review and meta-analysis , 2020, Intensive Care Medicine.
[6] Y. Zhong,et al. Risk Factors of Ventilator-Associated Pneumonia in Critically III Patients , 2019, Front. Pharmacol..
[7] Junyi Li,et al. Acinetobacter baumannii Ventilator-Associated Pneumonia: Clinical Efficacy of Combined Antimicrobial Therapy and in vitro Drug Sensitivity Test Results , 2019, Front. Pharmacol..
[8] Afsaneh Vazin,et al. In vitro activity of colistin in combination with various antimicrobials against Acinetobacter baumannii species, a report from South Iran , 2018, Infection and drug resistance.
[9] S. Taheri,et al. Interim Study: Comparison Of Safety And Efficacy of Levofloxacin Plus Colistin Regimen With Levofloxacin Plus High Dose Ampicillin/Sulbactam Infusion In Treatment of Ventilator-Associated Pneumonia Due To Multi Drug Resistant Acinetobacter , 2018, Iranian journal of pharmaceutical research : IJPR.
[10] R. Wunderink,et al. A global priority list of the TOp TEn resistant Microorganisms (TOTEM) study at intensive care: a prioritization exercise based on multi-criteria decision analysis , 2018, European Journal of Clinical Microbiology & Infectious Diseases.
[11] M. Kollef,et al. Acinetobacter Pneumonia: Improving Outcomes With Early Identification and Appropriate Therapy , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] A. Abdollahi,et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia. , 2018, Journal of comparative effectiveness research.
[13] I. Siriopol,et al. Endotracheal Tube Biofilm and its Impact on the Pathogenesis of Ventilator-Associated Pneumonia , 2018, Journal of critical care medicine.
[14] Y. Ye,et al. Activity of levofloxacin in combination with colistin against Acinetobacter baumannii: In vitro and in a Galleria mellonella model. , 2017, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.
[15] Eurosurveillance Editorial Team. Note from the editors: 10th European Antibiotic Awareness Day (EAAD) – raising awareness about prudent use of antimicrobials to help curb antimicrobial resistance , 2017, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.
[16] H. Fazeli,et al. Isolation of bacteriophages against multidrug resistant Acinetobacter baumannii , 2017, Research in pharmaceutical sciences.
[17] R. Moniri,et al. Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii , 2017, Iranian journal of microbiology.
[18] G. March,et al. A meta-analysis of in vitro antibiotic synergy against Acinetobacter baumannii. , 2015, Journal of microbiological methods.
[19] T. Schwartz,et al. Synergistic Effect of Membrane-Active Peptides Polymyxin B and Gramicidin S on Multidrug-Resistant Strains and Biofilms of Pseudomonas aeruginosa , 2015, Antimicrobial Agents and Chemotherapy.
[20] E. Giamarellos‐Bourboulis,et al. Time–kill effect of levofloxacin on multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: synergism with imipenem and colistin , 2015, European Journal of Clinical Microbiology & Infectious Diseases.
[21] M. Etminan,et al. Risk of acute kidney injury associated with the use of fluoroquinolones , 2013, Canadian Medical Association Journal.
[22] S. Sriwiriyajan,et al. Comparison of the Pharmacodynamics of Meropenem in Patients with Ventilator-Associated Pneumonia following Administration by 3-Hour Infusion or Bolus Injection , 2005, Antimicrobial Agents and Chemotherapy.
[23] B. Lomaestro. Fluoroquinolone-Induced Renal Failure , 2000, Drug safety.
[24] Jumaa Naser. Synergistic Effect of Silver Nanoparticles and Polymyxin B on Multidrug-resistant Acinetobacter baumannii Isolated from Burn Wound Infections , 2018 .